Influence Of Combined Medication On Comprehensive Treatment Of Moderate To Severe Ulcerative Colitis Patients With Anxiety And Depression

Objective Observing the incidence of anxiety and depression in patients with moderate-to-severe ulcerative colitis.To explore the clinical efficacy and improvement of flupentixol and melitracen combined with vedelizumab in patients with moderate to severe ulcerative colitis complicated with anxiety and depression,compared to vedolizumab alone,to provide a basis for comprehensive treatment of UC.Methods From September 2020 to January 2022,27 patients with moderate-to-severe active UC complicated with anxiety and depression from outpatient and inpatient visits to Hangzhou First People’s Hospital Affiliated to Zhejiang University School of Medicine were selected.All patients were randomized into a control group with vedolizumab alone and a treatment group with flupentixol and melitracen in combination.There were 14 cases in the control group and 13 cases in the treatment group.The control group was treated with vedelizumab alone.The treatment group was combined with flupentixol and melitracen based on the same administration as the control group.After 8 weeks of observation,the clinical symptoms,modified Mayo score and the improvement of anxiety and depression were compared between the two groups.Results Among the 49 cases of moderate-to-severe ulcerative colitis counted in this study,there were 27 patients with anxiety and depression,accounting for 55.1%（27/49）.There were 14 patients in the control group and 13 patients in the flupentixol and melitracen group.In the flupentixol and melitracen treatment group,11 cases were effective and 2 cases were ineffective,with a total effective rate of 84.6%（11/13）;in the control group,10 cases were effective and 4 cases were ineffective,with an overall effective rate of 71.4%（10/14）.After 8 weeks,the modified Mayo score,HAMA score and HAMD score in the flupentixol and melitracen treatment group were lower than those in the control group.Conclusion Patients with moderate-to-severe ulcerative colitis are often accompanied by anxiety and depression;vedolizumab has a definite clinical effect in the treatment of moderate-to-severe ulcerative colitis,and the long-term maintenance treatment effect is significant;moderate-to-severe ulcerative colitis complicated with anxiety,Combining flupentixol and melitracen combined therapy on the basis of first-line treatment with vedolizumab in patients with depression can help patients improve clinical efficacy,improve anxiety and depression,and improve quality of life.